Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 13, 2020updated 29 Oct 2021 9:05am

Mallinckrodt explores iNO as potential Covid-19 therapy

Mallinckrodt has started exploring inhaled nitric oxide (iNO) as a potential supportive measure for COVID-19 patients with pulmonary complications.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Mallinckrodt has started exploring inhaled nitric oxide (iNO) as a potential supportive measure for COVID-19 patients with pulmonary complications.

The company partnered with the US Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) to assess the potential use of iNO.

Mallinckrodt markets iNO as INOmax in the US to treat term and near-term newborns suffering from hypoxic respiratory failure caused by pulmonary hypertension.

The company conducted in-vitro testing of nitric oxide’s inhibitory effect on the replication cycle of SARS-CoV. In a separate study, iNO was used to treat six SARS-CoV patients, compared to eight controls.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Findings showed improvements in blood oxygenation, decrease in supplemental oxygen and the amount of ventilator support.

iNO was assessed in randomised controlled trials in paediatrics and adults with acute respiratory distress syndrome (ARDS) caused by respiratory viruses such as coronaviruses.

During one study, iNO demonstrated a partially dose-dependent improvement in blood oxygenation and reduced pulmonary artery pressure.

Data from the second trial in paediatric ARDS patients showed improvements in the composite measure of days alive or free of ventilator support at day 28.

Mallinckrodt executive vice-president and chief scientific officer Steve Romano said: “Mallinckrodt is evaluating the limited data presently available on inhaled nitric oxide as a supportive measure for treating coronavirus-associated lung complications.

“We are in ongoing discussions with scientific, regulatory and governmental organisations regarding the potential use of iNO in assisting with this global emergency, and are committed to determining whether iNO has a benefit for those diagnosed with COVID-19. We will share updates as information becomes available.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU